Infinitum Asset Management LLC raised its position in Benitec Biopharma Limited (NASDAQ:BNTC - Free Report) by 435.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,125,000 shares of the biotechnology company's stock after acquiring an additional 915,000 shares during the period. Benitec Biopharma makes up approximately 4.7% of Infinitum Asset Management LLC's holdings, making the stock its 6th biggest holding. Infinitum Asset Management LLC owned 4.80% of Benitec Biopharma worth $14,636,000 at the end of the most recent quarter.
Other institutional investors also recently bought and sold shares of the company. Ameriprise Financial Inc. boosted its stake in Benitec Biopharma by 138.4% in the fourth quarter. Ameriprise Financial Inc. now owns 35,476 shares of the biotechnology company's stock valued at $448,000 after acquiring an additional 20,597 shares in the last quarter. Northern Trust Corp boosted its stake in Benitec Biopharma by 54.2% in the fourth quarter. Northern Trust Corp now owns 38,200 shares of the biotechnology company's stock valued at $482,000 after acquiring an additional 13,425 shares in the last quarter. Informed Momentum Co LLC acquired a new stake in Benitec Biopharma in the first quarter valued at approximately $512,000. MYDA Advisors LLC boosted its stake in Benitec Biopharma by 4.0% in the first quarter. MYDA Advisors LLC now owns 52,000 shares of the biotechnology company's stock valued at $677,000 after acquiring an additional 2,000 shares in the last quarter. Finally, Lion Point Capital LP boosted its stake in Benitec Biopharma by 59.0% in the fourth quarter. Lion Point Capital LP now owns 62,000 shares of the biotechnology company's stock valued at $783,000 after acquiring an additional 23,000 shares in the last quarter. 52.19% of the stock is currently owned by institutional investors and hedge funds.
Benitec Biopharma Stock Performance
Shares of NASDAQ BNTC traded up $0.15 during midday trading on Tuesday, reaching $13.99. The company had a trading volume of 21,889 shares, compared to its average volume of 37,927. The company has a current ratio of 14.80, a quick ratio of 14.80 and a debt-to-equity ratio of 0.01. The business's 50-day simple moving average is $12.50 and its 200 day simple moving average is $13.34. Benitec Biopharma Limited has a 1 year low of $8.06 and a 1 year high of $17.15. The stock has a market cap of $367.24 million, a P/E ratio of -9.26 and a beta of 0.43.
Analyst Ratings Changes
A number of research firms have issued reports on BNTC. JMP Securities reaffirmed a "market outperform" rating and issued a $20.00 price target on shares of Benitec Biopharma in a report on Thursday, May 15th. HC Wainwright reaffirmed a "buy" rating and issued a $28.00 price target on shares of Benitec Biopharma in a report on Monday, May 19th. Finally, TD Cowen began coverage on shares of Benitec Biopharma in a report on Monday, July 7th. They issued a "buy" rating for the company. One research analyst has rated the stock with a Strong Buy rating and seven have given a Buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $26.00.
Get Our Latest Research Report on BNTC
Benitec Biopharma Company Profile
(
Free Report)
Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.
Read More
Before you consider Benitec Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Benitec Biopharma wasn't on the list.
While Benitec Biopharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
